Velabs Therapeutics GmbH
Biotechnology - Therapeutics and Diagnostics
Velabs Therapeutics is a spin-out company launched by Europe's most renowned institute for life sciences research, the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM). The institute has an outstanding track record in instrumentation development and is at the forefront of microfluidics-based screening technology and applications world-wide.
The company’s droplet-based microfluidic screening technology aims at the fast generation of antibodies against target molecules presented on cellular membrane surfaces or as soluble protein. VELABS has pioneered the use of droplet microfluidics for the fast screening of correctly paired human antibodies that do not just bind to a drug target, but rather modulate its function.